11 results about "Hydrochlorothiazide" patented technology

The invention discloses an olmesartan medoxomil pharmaceutical co-crystal as well as a preparation, a preparation method and application thereof. The co-crystal is formed by olmesartan medoxomil and a specific co-crystal forming agent through intermolecular force. The invention also particularly provides a compound preparation containing the olmesartan medoxomil pharmaceutical co-crystal and hydrochlorothiazide. Through the eutectic technology, the invention fundamentally overcomes the inherent defects of low solubility and slow dissolution of olmesartan medoxomil as a BCS II drug. Experiments show that the preparation disclosed by the invention can realize rapid and complete drug release in vitro (the dissolution rate within 30 minutes is greater than or equal to 98%), the relative bioavailability of olmesartan in vivo can be improved by at least 180% compared with that of a reference preparation, and meanwhile, the eutectic structure ensures that the preparation has excellent chemical stability under an accelerated test condition. The invention provides an innovative solution for the development of an efficient and stable olmesartan medoxomil preparation.

The invention relates to the technical field of particle raw material stirring and mixing, in particular to a compound dibazol hydrochlorothiazide capsule raw material pretreatment stirring and mixing device which comprises a plurality of treatment frames which are evenly distributed from top to bottom and provided with upward openings, discharging openings are formed in the bottoms of the treatment frames, and stirring mechanisms are installed in the treatment frames; the device adopts a manner of matching layered laying and alternate stacking, active ingredients are independently stirred and flattened, then the active ingredients and auxiliary materials are stacked layer by layer, the active ingredients are uniformly attached to the surfaces of the auxiliary materials through throwing, and multi-stage gradual dilution is carried out, so that the problem that the active ingredients are easy to disperse and non-uniform when being directly mixed can be solved, the medicine content accuracy is improved, and the medicine quality is improved. And the components of each capsule are uniform and reach the standard.

The invention discloses a telmisartan and hydrochlorothiazide compound tablet which is characterized in that the telmisartan and hydrochlorothiazide compound tablet comprises a double-layer tablet A and a double-layer tablet B, and the layer A is prepared from telmisartan lipidosome, a diluent and a lubricant; and the layer B is prepared from hydrochlorothiazide, a diluent, a disintegrating agent, a lubricant and an antioxidant. The telmisartan liposome comprises lipid and telmisartan, the dosage ratio of the lipid to the telmisartan is (0.5-2.3): 1, the lipid comprises phospholipid and cholesterol, and in the lipid, the content of the cholesterol accounts for 20%-60% of the total amount of the lipid. The telmisartan liposome comprises lipid, telmisartan and a PH buffer solution, and the PH of the PH buffer solution is 5-7. According to the telmisartan and hydrochlorothiazide compound tablet prepared by the invention, the telmisartan dissolution is good, and the tablet is safe and stable.

The present application relates to the technical field of hyperuricemia modeling, and particularly relates to a method for inducing and constructing a cynomolgus monkey hyperuricemia model and application thereof, comprising the following steps: S1: selecting male cynomolgus monkeys as model animals; S2: administering an inducing agent to the experimental animals, wherein the inducing agent is composed of hydrochlorothiazide, potassium oxonate and adenine. The inducing agent is added to ordinary monkey feed for normal feeding of the experimental animals, the intake dose of hydrochlorothiazide is 0.1 g / kg / day, the intake dose of potassium oxonate is 0.2 g / kg / day, the intake dose of adenine is 0.1 g / kg / day, and 10% fructose water is used to replace ordinary drinking water at the same time. The present application can induce a stable hyperuricemia state in the cynomolgus monkey body by means of dietary induction, combined use of hydrochlorothiazide, potassium oxonate and adenine, compared with a traditional model induced by a single intraperitoneal injection of a drug, the present application better simulates the pathogenic cause of human hyperuricemia, and is easier to operate.

The application discloses irbesartan and hydrochlorothiazide tablets and a preparation method thereof. The tablet comprises irbesartan granules and hydrochlorothiazide granules. The irbesartan granules comprise irbesartan, hydroxyphenyl cellulose, glycerophosphoric acid calcium, a disintegrant and a binder. The hydrochlorothiazide granules comprise hydrochlorothiazide, a diluent, a disintegrant and a binder. The tablet can solve the problems of easy agglomeration of irbesartan and hydrochlorothiazide, and difficulty in controlling the content uniformity due to the great difference in the dosage. Meanwhile, the tablet can effectively overcome the poor solubility of irbesartan and hydrochlorothiazide, and good dissolution effect is obtained.

The invention discloses a method for determining the content of formaldehyde in a hydrochlorothiazide bulk drug, which comprises the following steps: precisely weighing a formaldehyde solution, adding acetonitrile, an acetonitrile solution of 2, 4-dinitrophenylhydrazine and a phosphoric acid solution, and diluting to prepare a reference substance solution; the method comprises the following steps: precisely weighing a hydrochlorothiazide bulk drug, adding acetonitrile, an acetonitrile solution of 2, 4-dinitrophenylhydrazine and a phosphoric acid solution, and diluting to prepare a test solution; the method comprises the following steps: precisely measuring an acetonitrile solution of 2, 4-dinitrophenylhydrazine, a phosphoric acid solution and 1ml of acetonitrile, and diluting with acetonitrile to prepare a blank solution; analyzing by adopting high performance liquid chromatography, precisely measuring the blank solution, the test solution and the reference substance solution, respectively injecting into a liquid chromatograph, recording chromatograms, and calculating by peak area according to an external standard method to obtain the content of formaldehyde in the hydrochlorothiazide bulk drug. The method has the remarkable effects that the method has the characteristics of simple process, low use cost, good precision, high accuracy and the like, and the content of formaldehyde in the hydrochlorothiazide bulk drug can be rapidly measured.

The invention provides a losartan potassium and hydrochlorothiazide pharmaceutical composition and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, the composition is a tablet, and comprises the following components by weight: 15%-25% of losartan potassium, 5%-10% of hydrochlorothiazide, 10%-30% of a hydrophilic polymer carrier, 0.1%-5% of a pH regulator, 40%-60% of a filler, 3%-15% of a disintegrating agent, 0.5%-2% of a lubricant, and 1%-5% of an adhesive. The preparation method is divided into two methods, one method is a dry granulation process, material pretreatment is firstly carried out, and then tabletting is carried out after primary granulation, premixing, secondary granulation and total mixing; and the other method is a direct mixing process, the particle size of the solid dispersion is controlled after the materials are pretreated, and premixing, total mixing and direct tabletting are performed. According to the invention, the bioavailability of hydrochlorothiazide can be effectively improved, the drug can be rapidly dissolved out to take effect, the long-term stability of the preparation is obviously improved, the process reproducibility is good, and the preparation is suitable for industrial production.

The invention provides an irbesartan solid dispersion and a preparation method of a preparation thereof, and belongs to the technical field of pharmaceutical preparations, the irbesartan solid dispersion is prepared from 10-30% by weight of irbesartan, 60-90% by weight of copovidone and 5-15% by weight of a plasticizer by adopting a twin-screw hot melt extrusion process, and the irbesartan solid dispersion is prepared from the preparation method of the irbesartan solid dispersion and the preparation of the irbesartan solid dispersion. And mixing the solid dispersion with a filling agent, a disintegrating agent and a lubricating agent which are conventional in pharmaceutics to prepare irbesartan unilateral tablets, or additionally adding hydrochlorothiazide and mixing to prepare irbesartan compound tablets. According to the irbesartan tablet and the preparation method thereof, irbesartan is prepared into the solid dispersion and then prepared into the tablet, so that the electrostatic agglomeration of irbesartan is improved to improve the mixing uniformity of the preparation, the dissolution performance of irbesartan is remarkably improved, and the bioavailability of the medicine is improved; therefore, the problems of insufficient subsequent mixing uniformity caused by electrostatic agglomeration in irbesartan preparation preparation and poor dissolution performance and low bioavailability caused by low solubility are effectively solved.

The invention discloses a candesartan cilexetil and hydrochlorothiazide compound preparation and a preparation method thereof. The preparation method comprises the following steps: preparing a solid dispersion from candesartan cilexetil and a Soluplus (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol grafted copolymer)-TPGS (vitamin E polyethylene glycol succinate) dual-carrier system by adopting a low-temperature hot-melt extrusion technology, mixing the solid dispersion with hydrochlorothiazide granulated by a fluidized bed, and tabletting. The dissolution speed and bioavailability of candesartan cilexetil are improved, and the stability of the product is ensured.

The application discloses a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide and a preparation method thereof. The triple combination preparation comprises three active ingredients of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide, and further comprises pre-gelatinized starch, silicified microcrystalline cellulose, cross-linked carboxymethyl cellulose, polylactic acid spray-dried powder and tocopherol as auxiliary materials. The triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide is coated to obtain olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide tablets, which have the same dissolution stability as the original research product, a very smooth surface, no indentation and more stable quality.

This invention discloses a method for purifying hydrochlorothiazide, comprising dissolving crude hydrochlorothiazide in a mixture containing acid and solvent under heating conditions; then neutralizing with alkali under cooling conditions; and finally obtaining purified hydrochlorothiazide by cooling, crystallization, and filtration. The method provided by this invention further improves both the quality and purification yield of the hydrochlorothiazide product.